RCTs. It should be mentioned that PS was not found in 25% of patients. Therefore, real-world data are a valuable addition to trial results because they deepen the understanding of the outcome of therapies in patients encountered on a day-to-day basis
Search Results
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
Bishal Gyawali
or none a decade ago, but the billion dollar question is whether outcomes for patients with advanced liver cancer have improved as a result. Some of the statistics are concerning. Although it is too early to observe the effect of new drug approvals
Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group
: TCS completed a questionnaire regarding health outcomes, lifestyle behaviors, and current prescription medications (including antihypertensive, diabetic, and lipid-lowering medications). Demographic information included age at cancer diagnosis and
Maxwell T. Vergo and Amelia M. Cullinan
process, and therefore involvement at least 3 to 6 months before cessation of chemotherapy would be ideal to affect outcomes. Figure 1. Palliative care integrated into the continuum of care. Applying these criteria to the present case, Mr
David D. Buethe and Julio Pow-Sang
remains to optimize the criteria that qualify a man as either low risk or very low risk, and to establish standardized criteria defining disease progression. Further, there is a paucity of reports on the long-term outcomes of men electing to delay or forgo
P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose
studies of AS in intermediate-risk disease have been limited by small sample sizes, short follow-up, and lack of definitive clinical outcomes, including metastasis and prostate cancer–specific mortality (PCSM). 5 – 12 Nevertheless, the use of AS in
Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li
recurrence, leading to a poor prognosis. 4 Therefore, there is an urgent need for adjuvant treatment intensification to prevent disease recurrence and improve survival outcomes. Currently, mitotane monotherapy, cytotoxic drugs, and radiotherapy (RT) are
Neethi Dasu, Kirti Dasu, Jason John, Yaser Khalid, Lucy Joo, Brian Blair, and C. Jonathan Foster
, duodenal stents are used to treat patients who are considered high-risk surgical candidates. We aimed to study the survival and clinical outcomes after endoscopic duodenal stent placement for patients with pancreatic cancer in comparison to patients who do
Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
Background Immune checkpoint inhibitor (ICI) therapy significantly improves cancer outcomes by targeting CLTA-4 or PD-1/L1 and boosting T-cell–mediated immune responses and antitumor effects. 1 , 2 ICIs are widely used as first-line therapy
Haider Abdulraheem Alalawy
tongue surgery approach. The surgical defect was reconstructed by PMMF. The functional outcome was measured using the University of Washington Quality of Life Questionnaire (UW-QOL). Oncologic and functional outcome evaluated during the follow up period
